NCOA4
Nuclear receptor coactivator 4
Protein Summary
Enhances the androgen receptor transcriptional activity in prostate cancer cells. Ligand-independent coactivator of the peroxisome proliferator-activated receptor (PPAR) gamma. This gene encodes an androgen receptor coactivator. The encoded protein interacts with the androgen receptor in a ligand-dependent manner to enhance its transcriptional activity. Chromosomal translocations between this gene and the ret tyrosine kinase gene, also located on chromosome 10, have been associated with papillary thyroid carcinoma. Alternatively spliced transcript variants have been described. Pseudogenes are present on chromosomes 4, 5, 10, and 14. [provided by RefSeq, Feb 2009]
- ENST00000578454
- ENSP00000463027
- ENSG00000266412
- ENST00000579039
- ENSP00000463455
- ENST00000581486
- ENSP00000462943
- ENST00000583565
- ENSP00000463476
- ENST00000585132
- ENSP00000464054
- ARA70
- ELE1
- RFG
- RFG
- ELE1
- PTC3
- ARA70
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
kinase perturbation | 0.97 | ||
disease perturbation | 0.9 | ||
transcription factor binding site profile | 0.89 | ||
transcription factor perturbation | 0.74 | ||
transcription factor | 0.72 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 267 (req: < 5)
Gene RIFs: 49 (req: <= 3)
Antibodies: 345 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 267 (req: >= 5)
Gene RIFs: 49 (req: > 3)
Antibodies: 345 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 7
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0